8-K: Mirum Pharmaceuticals Exceeds 2024 Sales Guidance, Projects Strong Growth for 2025

Mirum Pharmaceuticals announced preliminary unaudited 2024 net product sales of approximately $336 million, exceeding the upper end of its guidance, and provided a 2025 sales outlook of $420 to $435 million.

Summary

• Mirum Pharmaceuticals reported preliminary unaudited net product sales of approximately $336 million for 2024, surpassing the high end of their guidance.
• The company anticipates global net product sales between $420 million and $435 million in 2025.
• LIVMARLI net product sales were approximately $213 million in 2024, while CHOLBAM and CHENODAL sales totaled about $123 million.
• In the fourth quarter of 2024, total net product sales were approximately $99 million, with $64 million from LIVMARLI and $35 million from CHOLBAM and CHENODAL.
• Mirum achieved positive cash flow from operations in the third quarter of 2024.
• As of December 31, 2024, the company's cash, cash equivalents, and investments were approximately $287 million, compared to $286.3 million at the end of 2023.
• The VISTAS study for volixibat in primary sclerosing cholangitis is expected to complete enrollment in the second half of 2025, with topline data expected in 2026.
• The VANTAGE study for volixibat in primary biliary cholangitis is expected to complete enrollment in 2026.
• The LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions is expected to complete enrollment in 2026.
• The FDA PDUFA date for chenodiol in cerebrotendinous xanthomatosis is March 28, 2025.
• Mirum plans to initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome in 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong sales performance, positive future guidance, and progress in clinical trials. The company's financial stability and pipeline advancements contribute to a favorable outlook.

Positives

• Mirum exceeded its 2024 net product sales guidance, indicating strong commercial performance.
• The company is projecting significant revenue growth for 2025, with sales expected to reach $420 to $435 million.
• Mirum has a strong cash position of approximately $287 million, providing financial stability.
• The company achieved positive cash flow from operations in Q3 2024, demonstrating improved financial efficiency.
• Mirum is advancing its pipeline with multiple clinical trials expected to reach key milestones in the near future.
• The company has expanded its global footprint to 30 countries, including successful launches in major European markets.
• Mirum has received breakthrough therapy designation for volixibat in PBC, highlighting its potential in this area.

Negatives

• The financial data for 2024 is preliminary and unaudited, subject to completion of financial closing procedures.
• The company's cash balance only slightly increased from $286.3 million at the end of 2023 to $287 million at the end of 2024.

Risks

• The 2024 financial results are preliminary and subject to change upon completion of the audit.
• Clinical trial timelines are subject to change, and there is no guarantee that studies will be completed on schedule.
• Regulatory approvals are not guaranteed, and the PDUFA date for chenodiol could be delayed.
• The company's future success depends on the commercial success of its products and the development of its pipeline.
• There are risks associated with the company's dependence on third-party manufacturers and suppliers.
• The company faces competition from other pharmaceutical companies in the rare disease space.

Future Outlook

Mirum expects continued revenue growth with global net product sales of approximately $420 million to $435 million in 2025 and anticipates positive cash flow from operations. The company also anticipates several clinical trial milestones and regulatory decisions in the coming years.

Management Comments

• Chris Peetz, chief executive officer of Mirum, stated that 2024 was a significant year for Mirum as they accelerated their commercial business and achieved significant development milestones.
• Mr. Peetz also mentioned that Mirum continued its leadership in cholestatic disease with a label expansion for LIVMARLI and positive interim analyses for volixibat in PSC and PBC.
• He further noted the advancement of rare genetic neurology efforts with the NDA submission for chenodiol and the in-licensing of MRM-3379 for Fragile X syndrome.
• Mr. Peetz believes that Mirum is well-positioned for sustained growth in the years ahead due to proven commercial execution in ultra-rare disease and a compelling pipeline in larger indications.

Industry Context

This announcement highlights Mirum's strong position in the rare disease market, particularly in cholestatic liver diseases and genetic neurology. The company's focus on developing and commercializing treatments for these conditions aligns with the growing trend of pharmaceutical companies targeting niche markets with high unmet needs. The positive sales figures and pipeline progress position Mirum as a key player in this space, potentially impacting competitors focused on similar therapeutic areas.

Comparison to Industry Standards

• Mirum's 2024 net product sales of $336 million demonstrate strong growth compared to previous years, indicating successful commercialization of its products.
• The projected 2025 sales of $420-$435 million suggest continued growth, which is a positive sign for investors.
• Compared to companies like Travere Therapeutics, which also focuses on rare diseases, Mirum's growth trajectory appears robust, especially with the expansion of LIVMARLI and the development of volixibat.
• The company's focus on cholestatic liver diseases and genetic neurology positions it well in a market with high unmet needs, similar to companies like Albireo Pharma, which also targets rare liver diseases.
• The positive interim results for volixibat in PSC and PBC are promising, as there are limited approved therapies for these conditions, giving Mirum a competitive edge.
• The PDUFA date for chenodiol in CTX is a significant milestone, as it could provide a new treatment option for this rare disease, similar to how other companies have gained market share with orphan drug approvals.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong sales results and positive future outlook.
• Employees may feel more secure due to the company's financial stability and growth prospects.
• Patients with rare diseases may benefit from the company's continued development of new treatments.
• Customers will have access to more treatment options as Mirum expands its product portfolio.
• Suppliers and creditors may view Mirum as a reliable partner due to its strong financial position.

Next Steps

• Mirum will present at the J.P. Morgan Healthcare Conference on January 15, 2025.
• The company will continue to enroll patients in the VISTAS, VANTAGE, and EXPAND studies.
• Mirum will prepare for the FDA PDUFA date for chenodiol on March 28, 2025.
• The company plans to initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome in 2025.

Key Dates

Keywords

Mirum Pharmaceuticals, LIVMARLI, volixibat, CHOLBAM, chenodiol, rare diseases, cholestatic pruritus, primary sclerosing cholangitis, primary biliary cholangitis, Fragile X Syndrome, net product sales, clinical trials, FDA approval, PDUFA date, orphan drug designation